CSF1 and neoplasm: Other pharmaceutical agents, including the CCL2 inhibitor bindarit, anti-CCL2 mAb carlumab, CSF1 inhibitor GW2580, and dequalinium-14, CD40 antagonist CP-870,893, have also shown anti-tumor effects by reducing macrophage infiltration (DeNardo and Ruffell, 2019).